Base de données - (CIANE)

Présentation de cette base de données documentaires (site du CIANE)
Actuellement 3111 fiches
➡ Chaîne YouTube (tutoriel)

https://ciane.net/id=2821

Créée le : 26 Nov 2017
Modifiée le : 26 Nov 2017

➡ Modifier cette fiche
Ne suivez ce lien que si vous possédez un mot de passe d’éditeur !

Notice bibliographique (sans auteurs) :

Induction of labour in nulliparous and multiparous women: A UK, multicentre, open-label study of intravaginal misoprostol in comparison with dinoprostone - BJOG: An International Journal of Obstetrics and Gynaecology - Vol. 115, 10 - p.1279-1288

Auteur·e(s) :

Calder, A.A.; Loughney, A.D.; Weir, C.J.; Barber, J.W.

Année de publication :

2008

URL(s) :

https://www.scopus.com/inward/record.uri?eid=2-s2.…
https://doi.org/10.1111/j.1471-0528.2008.01829.x

Résumé (français)  :

Abstract (English)  :

Objective: To compare the efficacy and safety of a 25-microgram vaginal tablet of misoprostol (APL202) with dinoprostone (3-mg vaginal tablet) in cervical ripening and labour induction. Design: A randomised, open-label, noninferiority, comparative study in two maternal populations. Setting: Eighteen NHS study centres across the UK. Population: Nulliparous or multiparous women with a singleton pregnancy eligible for induction of labour. Methods: Women were randomised to receive either misoprostol, initially 25 micrograms (50 micrograms in nulliparous women with Bishop score ≤4) followed by 25 micrograms after 4 and 8 hours, or dinoprostone, initially 3 mg followed by 3 mg after 6 hours. Clinical noninferiority of misoprostol was defined as an absolute difference between treatments of no more than 10% for the primary outcome. Main outcome measures: The number of vaginal deliveries achieved within 24 hours of labour induction. Maternal and fetal safety outcomes. Results: A total of 626 women were randomised to misoprostol (n = 318) or dinoprostone (n = 308) treatment. The rate of vaginal deliveries achieved within 24 hours of induction did not significantly differ between the misoprostol and dinoprostone (43 versus 47%; 3.74% difference, 95% CI -3.58 to 11.05, respectively) treatment groups. The treatments were generally comparable for other secondary efficacy measures. Maternal and fetal adverse events were similarly distributed across the misoprostol and dinoprostone groups. Conclusions: Low-dose misoprostol is efficacious in cervical ripening and labour induction and demonstrates a similar fetal and maternal safety profile to dinoprostone. © 2008 Alliance Pharmaceuticals Ltd.

Sumário (português)  :

Resumen (español)  :

Remarques :

Argument (français) :

Argument (English):

Argumento (português):

Argumento (español):

Mots-clés :

➡ déclenchement ; misoprostol (Cytotec)

Auteur·e de cette fiche :

Import 26/11/2017 — 26 Nov 2017